AZD9291 80 mg/40 mg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Stage IB-IIIA Non-small Cell Lung Carcinoma

Drug Information

Target Indication

Stage IB-IIIA Non-small Cell Lung Carcinoma

Clinical Trial

Last updated: 2/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Related Pipeline

Generalized Anxiety Disorder

Diabetes Mellitus, Type 2

Metastatic Castration-resistant Prostate Cancer

Triple Negative Breast Neoplasms

Rheumatoid Arthritis